Inhibikase swaps 18M shares for pre-funded warrant
Inhibikase Therapeutics, Inc. entered into an exchange agreement with RA Capital Healthcare Fund, L.P. on July 29, 2026.
Rhea-AI Filing Summary
Inhibikase Therapeutics, Inc. entered into an exchange agreement with RA Capital Healthcare Fund, L.P. on July 29, 2026. RA Capital exchanged 18,030,000 shares of common stock for a pre-funded warrant to acquire 18,030,000 shares of common stock.
The pre-funded warrant has a $0.001 exercise price per share, is immediately exercisable, has no expiration date, and is adjustable for stock splits and similar events. A beneficial ownership blocker generally limits RA Capital’s ownership upon exercise to 9.99% of outstanding common stock, adjustable with 61 days’ notice up to 19.99%. The warrant was issued in an unregistered exchange relying on Section 3(a)(9) of the Securities Act of 1933.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 3.02, 9.01
2 items
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Shares Exchanged: 18,030,000 shares
Warrant Underlying Shares: 18,030,000 shares
Exercise Price: $0.001 per share
+3 more
6 metrics
Shares Exchanged
18,030,000 shares
Common stock exchanged by RA Capital for the pre-funded warrant on July 29, 2026
Warrant Underlying Shares
18,030,000 shares
Number of common shares acquirable under the pre-funded warrant
Exercise Price
$0.001 per share
Exercise price of the pre-funded warrant for each underlying common share
Beneficial Ownership Blocker
9.99%
Initial cap on beneficial ownership upon warrant exercise
Maximum Ownership Cap
19.99%
Upper limit to which the beneficial ownership cap can be increased
Notice Period to Change Cap
61 days
Required prior notice to adjust the beneficial ownership threshold
Key Terms
pre-funded warrant, beneficial ownership blocker, Section 3(a)(9) of the Securities Act of 1933, Section 13(d) of the Securities Exchange Act of 1934
4 terms
pre-funded warrant financial
"exchanged 18,030,000 shares of our common stock for a pre-funded warrant"
A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.
beneficial ownership blocker regulatory
"The pre-funded warrant includes a beneficial ownership blocker that provides"
A beneficial ownership blocker is a legal or structural device that prevents a shareholder from being treated as the ultimate owner of enough shares to trigger control, reporting, or voting thresholds. Think of it like a speed bump that stops an investor from reaching a stake size that would force corporate disclosure or change control rights. Investors care because it affects who controls the company, how shares vote, regulatory filings, takeover risk and therefore potential value or liquidity of their holdings.
Section 3(a)(9) of the Securities Act of 1933 regulatory
"in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933"
Section 3(a)(9) of the Securities Act of 1933 is a limited registration exemption that lets holders swap one security for another issued by the same company—common in reorganizations, mergers, exchanges or bankruptcy—without the company having to register the transaction with the SEC. Think of it like trading in an old product for a new model from the same maker: investors care because it can speed restructuring, cut legal costs and paperwork, and affect when and how shares become tradable, which in turn influences liquidity and potential dilution.
Section 13(d) of the Securities Exchange Act of 1934 regulatory
"aggregated for the purposes of Section 13(d) of the Securities Exchange Act of 1934"
Section 13(d) of the Securities Exchange Act of 1934 is a U.S. rule that requires anyone who buys more than 5% of a public company’s shares to publicly disclose who they are, how many shares they own, and their intentions toward the company. For investors, this is like a neighborhood alert when someone acquires a large stake in a building: it reveals potential changes in control or strategy that could affect the stock’s price, governance, or future direction.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Inhibikase Therapeutics (IKT) agree with RA Capital on July 29, 2026?
Inhibikase Therapeutics and RA Capital entered an exchange agreement where 18,030,000 common shares held by RA Capital were exchanged for a pre-funded warrant to acquire 18,030,000 common shares. The economic exposure is maintained but now held through a warrant instrument.
What is the exercise price and term of the IKT pre-funded warrant issued to RA Capital?
The pre-funded warrant has an exercise price of $0.001 per share, is immediately exercisable, and has no expiration date. Its share count can be adjusted for corporate actions such as stock splits, stock dividends, combinations, and similar transactions.
What ownership limits apply to RA Capital’s pre-funded warrant in Inhibikase (IKT)?
The warrant has a beneficial ownership blocker that prevents exercises causing RA Capital and certain affiliates to exceed 9.99% ownership. This limit can be changed with 61 days’ prior notice, but not above an upper cap of 19.99% of outstanding common stock.
Under which securities law exemption was the IKT pre-funded warrant issued to RA Capital?
The pre-funded warrant was issued relying on Section 3(a)(9) of the Securities Act of 1933. This exemption applies to exchanges of securities with existing holders, allowing the transaction to proceed without registering the warrant under the Securities Act.
Does the RA Capital pre-funded warrant for IKT adjust for corporate actions?
Yes. The number of common shares issuable upon exercise of the pre-funded warrant is subject to adjustment for certain corporate events, including specified stock dividends, stock splits, combinations, and other similar transactions, helping preserve the warrant’s relative economic position over time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
